Linked Life Data

3024886

Source:http://linkedlifedata.com/resource/pubmed/id/3024886

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
1987-1-29
pubmed:abstractText
Previously we reported that the pre-transplant and pre-rejection OKT4/OKT8 ratio can be used to predict renal allograft survival. Patients on azathioprine (Aza) and low-dose steroids (St) with a pretransplant ratio less than or equal to 1.6 exhibited a 6-month graft survival of 33% compared with 79% for those with a ratio greater than 1.6 (P = 0.02). Furthermore, 100% of the rejection episodes treated with high doses of prednisone in patients with a prerejection ratio less than or equal to 1.6 were irreversible in comparison with only 10% for patients with a ratio greater than 1.6 (P less than 0.001). In the present study, we investigated the prognostic value of the OKT4/OKT8 ratio for patients who received rabbit antithymocyte globulin (RATG) as anti-rejection therapy or cyclosporin A (CsA) as basic immunosuppressive therapy. No correlation was found between the pre-transplant OKT4/OKT8 ratio and 6-month graft survival for either treatment group because of an improved graft survival among patients with a pretransplant ratio less than or equal to 1.6 (78% for patients who received RATG and 85% for CsA-treated patients). For Aza-treated patients with an OKT4/OKT8 ratio less than or equal to 1.6 at the time of rejection, rejection episodes that were treated with RATG were reversible in 78% of the cases, whereas among CsA-treated patients rejection episodes treated with high doses of prednisone were reversible in 72% of the cases. No significant differences in graft survival or reversibility of rejection episodes between patients with a pre-transplant or prerejection OKT4/OKT8 ratio greater than 1.6 were found. Furthermore, in both the CsA and the Aza-treated patients (with or without RATG), the OKT4/OKT8 ratio had decreased significantly 3 months after transplantation. This decrease was associated with cytomegalovirus infections rather than the type of immunosuppressive therapy.
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/3024886-315070, http://linkedlifedata.com/resource/pubmed/commentcorrection/3024886-3898491, http://linkedlifedata.com/resource/pubmed/commentcorrection/3024886-6093294, http://linkedlifedata.com/resource/pubmed/commentcorrection/3024886-6210475, http://linkedlifedata.com/resource/pubmed/commentcorrection/3024886-6219171, http://linkedlifedata.com/resource/pubmed/commentcorrection/3024886-6220816, http://linkedlifedata.com/resource/pubmed/commentcorrection/3024886-6232027, http://linkedlifedata.com/resource/pubmed/commentcorrection/3024886-6292304, http://linkedlifedata.com/resource/pubmed/commentcorrection/3024886-6373078, http://linkedlifedata.com/resource/pubmed/commentcorrection/3024886-6377607, http://linkedlifedata.com/resource/pubmed/commentcorrection/3024886-6401505, http://linkedlifedata.com/resource/pubmed/commentcorrection/3024886-6454075, http://linkedlifedata.com/resource/pubmed/commentcorrection/3024886-6457868
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Aug
pubmed:issn
0009-9104
pubmed:author
pubmed:issnType
Print
pubmed:volume
65
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
373-80
pubmed:dateRevised
2009-11-18
pubmed:meshHeading
pubmed:year
1986
pubmed:articleTitle
Prognostic value of T lymphocyte subset ratios for renal transplant survival in patients on different immunosuppressive regimens.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't